Osteopenia, osteoporosis, and fractures in HIV-infected patients: Extent of the problem

被引：3
作者：
V. Walker Harris
T. T. Brown
机构：
[1] Division of Endocrinology and Metabolism, Johns Hopkins University, School of Medicine, Baltimore, MD 21287
来源：
Clinical Reviews in Bone and Mineral Metabolism | 2012年 / 10卷 / 4期
基金：
美国国家卫生研究院;
关键词：
Bone mineral density; Fracture; HIV; Osteoporosis; Prevalence;
D O I：
10.1007/s12018-012-9132-z
中图分类号：
学科分类号：
摘要：
In HIV-infected persons, osteoporosis is common and has a multifactorial etiology including traditional risk factors, such as smoking and low body weight, as well as direct effects of HIV infection and antiretroviral therapy. Multiple studies indicate that HIV-infected persons are at increased risk of low bone mass as compared to the general population. Emerging data suggest that the increased prevalence of reduced bone mass in HIV infection predisposes patients to an increased risk of fracture. This review discusses the epidemiology of low bone mass and fracture in HIV-infected persons, addresses the multiple causes of reduced bone mineral density in HIV infection, and offers recommendations on screening HIV-infected persons for bone loss. © 2012 Springer Science+Business Media, LLC.
引用
收藏
页码：246 / 256
页数：10
相关论文
共 86 条
[1]  
Peck W.A., Burckhardt P., Christiansen C., Fleisch H.A., Genant H.K., Gennari C., Martin T.J., Martini L., Morita R., Ogata E., Rapado A., Shulman L.E., Stern P.H., Young R.T.T., Barrett-Connor E., Brandi M.L., Chesnut C.H., Delmas P.D., Heaney R.P., Et al., Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis, American Journal of Medicine, 94, 6, pp. 646-650, (1993)
[2]  
Who are candidates for prevention and treatment for osteoporosis?, Osteoporos Int, 7, 1, pp. 1-6, (1997)
[3]  
Johnell O., Kanis J.A., An estimate of the worldwide prevalence and disability associated with osteoporotic fractures, Osteoporosis International, 17, 12, pp. 1726-1733, (2006)
[4]  
Gallant J.E., Staszewski S., Pozniak A.L., DeJesus E., Suleiman J.M.A.H., Miller M.D., Coakley D.F., Lu B., Toole J.J., Cheng A.K., Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial, Journal of the American Medical Association, 292, 2, pp. 191-201, (2004)
[5]  
Tebas P., Powderly W.G., Claxton S., Marin D., Tantisiriwat W., Teitelbaum S.L., Yarasheski K.E., Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy, AIDS, 14, 4, (2000)
[6]  
Tebas P., Umbleja T., Dube M., Parker R., Mulligan K., Roubenoff R., Grinspoon S., Initiation of ART is associated with bone loss independent of the specific ART regimen: Results of ACTG A5005s, 14th Conference on Retroviruses and Opportunistic Infections, (2007)
[7]  
Brown T.T., Qaqish R.B., Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review, AIDS, 20, 17, pp. 2165-2174, (2006)
[8]  
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group, World Health Organ Tech Rep Ser., 843, pp. 1-129, (1994)
[9]  
Cazanave C., Dupon M., Lavignolle-Aurillac V., Barthe N., Lawson-Ayayi S., Mehsen N., Et al., Reduced bone mineral density in HIV-infected patients: Prevalence and associated factors, AIDS, 22, 3, pp. 395-402, (2008)
[10]  
Fernandez-Rivera J., Garcia R., Lozano F., Macias J., Garcia-Garcia J.A., Mira J.A., Corzo J.E., Gomez-Mateos J., Rueda A., Sanchez-Burson J., Pineda J.A., Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients, HIV Clinical Trials, 4, 5, pp. 337-346, (2003)
123456789